DUSA Pharmaceuticals (DUSA): Independent Study Utilizing Cyclic Levulan PDT Finds 95 Percent Reduction in New Squamous Cell Carcinoma Lesions in Solid Organ Transplant Recipients Over a 2-Year Period
11/10/2009 10:38:13 AM
More...
|
DUSA Pharmaceuticals (DUSA) Reports Third Quarter 2009 Corporate Highlights and Financial Results Q3 Domestic PDT
11/6/2009 10:00:36 AM
More...
|
DUSA Pharmaceuticals (DUSA) Announces Third Quarter Financial Results and Corporate Highlights Conference Call
11/3/2009 9:59:25 AM
More...
|
DUSA Pharmaceuticals (DUSA) Named to Deloitte's 2009 Technology Fast 500 List of Fastest Growing Companies in North America
10/21/2009 9:35:52 AM
More...
|
DUSA Pharmaceuticals (DUSA) Reports Second Quarter 2009 Corporate Highlights and Financial Results Q2
8/11/2009 9:45:31 AM
More...
|
DUSA Pharmaceuticals (DUSA) Reports First Quarter 2009 Corporate Highlights and Financial Results
5/12/2009 11:41:13 AM
More...
|
DUSA Pharmaceuticals (DUSA) Initiates Clinical Trial of Levulan(R) PDT on High-Risk Solid Organ Transplant Recipients
5/11/2009 11:46:25 AM
More...
|
DUSA Pharmaceuticals (DUSA) Announces First Quarter Financial Results and Corporate Highlights Conference Call
5/7/2009 11:16:30 AM
More...
|
DUSA Pharmaceuticals (DUSA) Reports Fourth Quarter and Full Year 2008 Corporate Highlights and Financial Results
3/11/2009 12:05:50 PM
More...
|
DUSA Pharmaceuticals (DUSA) to Host Fourth Quarter and Full Year 2008 Financial Results and Corporate Highlights Conference Call
3/6/2009 10:19:14 AM
More...
|
|